Jai Radhakrishnan, MD, discusses why IgG4-related kidney disease is often missed and what MITIGATE subgroup data presented at ASN Kidney Week 2026 show
|Videos|January 27, 2022
Trends in the Advancement of Health Care IT in 2022, Beyond
Shreejit Nair, senior vice president and life sciences market business lead at CitiusTech, discusses some trends and predictions for health care IT this year and on into the future.
Advertisement
Pharmacy Times interviewed Shreejit Nair, senior vice president and life sciences market business lead at CitiusTech, on how data interoperability can be enhanced within pharmacy and health systems to improve health care outcomes.
During the interview, Nair discussed some trends and predictions for advancements in the field of health care IT in 2022 and beyond.
Advertisement
Related to this article
Pharmacy Times featured experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during cold and influenza season.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
Pharmacy performance measures should recognize clinical interventions, patient counseling, prescriber collaboration, and outcomes—not prescription volume alone.
CMS’s GLP-1 Bridge demo bypasses Part D to cover select obesity drugs, with a $50 monthly copay, PA workflow, and strict eligibility through 2027.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
2
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
3
Beyond Prescription Volume: Measuring the Pharmacist’s Value
4
GLP-1 RAs, Finerenone, and CKD: Key Data From Kidney Week 2026
5